Clinical Trial Update: Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial update evaluating thalidomide with alpha interferon, with or without octreotide, in patients with unresectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Interferon Alfa (interferon alfa)
• OCTREOTIDE (OCTREOTIDE ACETATE)
• Thalidomide (thalidomide)

Snippet

Sponsor: University of New Mexico | Conditions: Liver, Cancer | Phase 2 | Status: COMPLETED